<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10045">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02976181</url>
  </required_header>
  <id_info>
    <org_study_id>Brady MX</org_study_id>
    <nct_id>NCT02976181</nct_id>
  </id_info>
  <brief_title>Brady MX a Quality Improvement Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medtronic is sponsoring a quality improvement study called Brady MX. It is hypothesized that
      lack of awareness of treatment and diagnostics pathways result in lower number of referrals
      to implanters of IPG.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Absolute change in the proportion of subjects diagnosed with SND at pre specific time.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of SND subjects receiving a referral for an indicated IPG device after the intervention</measure>
    <time_frame>6 months</time_frame>
    <description>The change between subjects referred to an indicated IPG will be measured after the intervention in total number of patients that are referred correctly.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Sinus Node Disfunction</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IPG</intervention_name>
    <description>Patient might require IPG device to be implanted under standard of care</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Bradycardia symptomatic patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient at least 18 years of age

          -  Patient´s heart rate meets at least one of the following:

        Patient has a sinus rate ≤ 50 OR a junctional escape rhythm no faster than 50 Patient has
        a history of exercise intolerance

          -  Patient complains of general fatigue, shortness of breath, shortness of breath with
             exertion, syncope, light headed dizziness, palpitations, lethargy, dyspnea OR malaise
             within the last 30 days that are not related to other discovered causes (such as
             untreated hypothyroidism or anemia)

          -  Patient (or patient´s legally authorized representative) is willing and able to sign
             and date written Patient Consent Form/Data Release Form

        Exclusion Criteria:

          -  Patient has recent history of blood loss

          -  Patient has a medical history leading to suspicion of neurological disorder

          -  Patient has a history of Chronic Atrial Fibrilation

          -  Patient is enrolled or planing to participate in a concurrent drug and/or device
             study at any time during the course of this clinical study without documented
             pre-approval from Medtronic study manager

          -  Patient is not expected to survive 12 months

          -  Patient is anticipated to be unwilling or unable to comply with the clinical
             investigation plan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Hernandez</last_name>
    <phone>+525511029044</phone>
    <email>maria.a.hernandez@medtronic.com</email>
  </overall_contact>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 24, 2016</lastchanged_date>
  <firstreceived_date>July 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sick Sinus Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
